2 research outputs found

    Natural single amino acid polymorphism (F19Y) in human galectin-8: detection of structural alterations and increased growth-regulatory activity on tumor cells

    Get PDF
    39 p.-10 fig.-3 tab.Natural amino acid substitution by single-site nucleotide polymorphism can become a valuable tool for structure-activity correlations, especially if evidence for association to disease parameters exists. Focusing on the F19Y change in human galectin-8, connected clinically to rheumatoid arthritis, we here initiate the study of consequences of a single-site substitution in the carbohydrate recognition domain of this family of cellular effectors. We apply a strategically combined set of structural and cell biological techniques for comparing properties of the wild type and variant proteins. The overall hydrodynamic behavior of the full-length protein and of the separate N-domain is not noticeably altered, but displacements in the F0 β-strand of the β-sandwich fold in the N-domain are induced, as evidenced by protein crystallography. Analysis of thermal stability by circular dichroism spectroscopy revealed perceptible differences for the full-length proteins, pointing to an impact of the substitution beyond the N-domain. In addition, small differences in thermodynamic parameters of carbohydrate binding are detected. On the level of two types of tumor cells, characteristics of binding appeared rather similar. In further comparison of influence on proliferation, the variant proved to be more active as growth regulator in the six tested lines of neuroblastoma, erythroleukemia and colon adenocarcinoma. The seemingly subtle structural change identified here thus has functional implications in vitro, encouraging further analysis in autoimmune regulation and, in a broad context, work with other natural single-site variants, using the documented combined strategy.This work was generously supported by grants BFU2009-10052, BFU2011-24615, BFU2012-36825 and CSD2009-00088 from the Spanish Ministry of Science and Innovation, the CIBER of Respiratory Diseases (CIBERES), an initiative from ISCIII, the Regional Government of Madrid (S2010/BMD-2353 and S2010/BMD-2457) and funding from the European Union’s Seventh Framework Program FP7/2007-2013 under REA grant agreements no. 260600 (GlycoHIT) and 317297 (GLYCOPHARM), F.M.R. by an ESF/CSIC funded JAE-Doc Contract.Peer reviewe
    corecore